All public logs

Combined display of all available logs of Glioblastoma Treatments. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).

• 10:47, 28 April 2024 Lazy talk contribs created page Sulforaphane (Created page with "{{TreatmentInfo |drug_name=Sulforaphane |FDA_approval=No (Used as a dietary supplement; not FDA-approved for cancer treatment) |used_for=Investigational use in cancer treatment, particularly in preclinical studies focusing on glioblastoma |clinical_trial_phase=Preclinical studies |clinical_trial_explanation=Sulforaphane is being studied in preclinical models for its potential as an anti-cancer agent against glioblastoma. Research focuses on its ability to inhibit histone...")
• 10:46, 28 April 2024 Lazy talk contribs created page Resveratrol (Created page with "{{TreatmentInfo |drug_name=Resveratrol |FDA_approval=No (Used as a dietary supplement; not FDA-approved for cancer treatment) |used_for=Investigational use in cancer treatment and prevention; also studied for cardiovascular benefits and anti-aging properties |clinical_trial_phase=Preclinical studies and early clinical trials |clinical_trial_explanation=Resveratrol is being studied for its potential anti-cancer properties in preclinical and early clinical trials, focusing...")
• 21:19, 5 April 2024 Lazy talk contribs created page Beta-blockers (especially propranolol) and the role of the sympathetic (Created page with " {{TreatmentInfo |drug_name=Beta-blockers (especially propranolol) and the role of the sympathetic |category=Hormones and Cancer Therapy |book_text=nervous system Recenty the role of the sympathetic nervous system in cancer progression, and the potential role of beta-adrenergic antagonists (beta-blockers) have come into focus in some corners of the cancer research community. Early studies linking stress to increased rates of cancer progression led to epidemiological st...")
• 21:19, 5 April 2024 Lazy talk contribs created page Angiotensin-Il Receptor Blockers (ARB) (Created page with " {{TreatmentInfo |drug_name=Angiotensin-Il Receptor Blockers (ARB) |category=Hormones and Cancer Therapy |book_text=Angiotensin-II is a peptide hormone produced from angiotensin-I by the action of angiotensin converting enzyme (ACE). The main effect of angiotensin-II is vasoconstriction and a resulting increase in blood pressure. Therefore ACE inhibitors and angiotensin-II receptor blockers are used as anti-hypertensive drugs, especially in heart disease. More recently...")
• 21:18, 5 April 2024 Lazy talk contribs created page Herpes Virus (Created page with " {{TreatmentInfo |drug_name=Herpes Virus |category=Oncolytic virotherapy |book_text=Another virus used in cancer therapy is a modified form of the herpes virus. Initial trials used a retrovirus version, which infects only those cells dividing when the virus was infused. Subsequent trials have used an adenovirus version, which infects both dividing and non-dividing cells. Because the herpes virus can be lethal to the brain if allowed to proliferate, soon after the virus...")
• 21:18, 5 April 2024 Lazy talk contribs created page Newcastle Disease Virus (Created page with " {{TreatmentInfo |drug_name=Newcastle Disease Virus |category=Oncolytic virotherapy |book_text=An alternative approach to vaccine treatment utilizes viruses. Newcastle disease is a lethal chicken disease, which is caused by a virus that is innocuous to humans, causing only transitory mild flu-like symptoms. It was developed as a cancer treatment in Hungary but has largely been ignored in this country until only recently. Newcastle Disease Virus is currently being utiliz...")
• 21:18, 5 April 2024 Lazy talk contribs created page DNX-2401 adenovirus (Created page with " {{TreatmentInfo |drug_name=DNX-2401 adenovirus |category=Oncolytic virotherapy |book_text=Another viral therapy in phase 1 has had impressive results, comparable to the PVS-RIPO trial. DNX-2401 is a modified adenovirus that is directly injected into the tumor. Preliminary results of a phase 1 trial at MD Anderson in Houston, Texas were presented at the November 2014 SNO conference in Miami. 37 recurrent high-grade glioma patients had been treated, with no adverse event...")
• 21:18, 5 April 2024 Lazy talk contribs created page Genetically modified Poliovirus (PVS-RIPO) (Created page with " {{TreatmentInfo |drug_name=Genetically modified Poliovirus (PVS-RIPO) |category=Oncolytic virotherapy |book_text=In 2015, this phase I trial for recurrent glioblastoma at Duke University received a boost in public interest when an episode of the television show 60 minutes was devoted to it. Most exceptionally, the first two patients treated in this study were complete responders. As of March 2015 (when the 60 minutes special aired) these two complete responders were st...")
• 14:27, 31 March 2024 Lazy talk contribs created page Wilms Tumor 1 (WT1) Peptide Vaccine (Created page with "{{TreatmentInfo |drug_name=Wilms Tumor 1 (WT1) Peptide Vaccine |FDA_approval=In clinical trials; not yet FDA-approved |used_for=Newly diagnosed and recurrent Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase II (Based on the latest clinical trial data available) |common_side_effects=Local erythema at the injection site; overall, the treatment is well-tolerated |OS_without=Typical median overall survival for GBM with standard treatment is about 15-17 months |OS_wi...")
• 14:23, 31 March 2024 Lazy talk contribs created page Rindopepimut (CDX-110) (Created page with "{{TreatmentInfo |drug_name=Rindopepimut (CDX-110) |FDA_approval=Not FDA-approved; received Breakthrough Therapy designation for glioblastoma in Feb 2015 |used_for=EGFRvIII-positive Glioblastoma Multiforme (GBM) in newly diagnosed and recurrent cases |clinical_trial_phase=Phase III for newly diagnosed GBM was discontinued; Phase II for recurrent GBM showed promising results |common_side_effects=Transient, low-grade local reactions; overall well-tolerated |OS_without=Media...")
• 14:19, 31 March 2024 Lazy talk contribs created page Anti-CMV Dendritic Cell Vaccine (Created page with "{{TreatmentInfo |drug_name=Anti-CMV Dendritic Cell Vaccine |FDA_approval=In clinical trials; not yet FDA-approved |used_for=Newly diagnosed and recurrent Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase II |common_side_effects=Not detailed; dendritic cell vaccines are generally well-tolerated with mild side effects. |OS_without=Historical controls indicate median overall survival around 15-17 months for newly diagnosed GBM. |OS_with=Varied; one study showed medi...")
• 14:14, 31 March 2024 Lazy talk contribs created page SL-701 (Created page with "{{TreatmentInfo |drug_name=SL-701 (Immunotherapy Vaccine) |FDA_approval=In clinical trials; not yet FDA-approved |used_for=Relapsed or refractory Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase II |common_side_effects=Fatigue, injection site reaction, erythema, and pain were the most common treatment-related adverse events. No grade 4/5 adverse events reported, indicating a manageable safety profile. |OS_without=Historical controls suggest a median overall surv...")
• 14:10, 31 March 2024 Lazy talk contribs created page ICT-107 (Created page with "{{TreatmentInfo |drug_name=ICT-107 (Tumor-associated Antigen Vaccine) |FDA_approval=Still in clinical trials; not yet FDA-approved |used_for=Newly diagnosed and recurrent Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase III |common_side_effects=Reported side effects are minimal, including potential site reactions and flu-like symptoms. Few serious adverse events related to the vaccine have been reported. |OS_without=Median overall survival for GBM typically rang...")
• 14:06, 31 March 2024 Lazy talk contribs created page Agenus Prophage (Heat-Shock Protein Peptide Complex-96) Vaccine (Created page with "{{TreatmentInfo |drug_name=Agenus Prophage (Heat-Shock Protein Peptide Complex-96) Vaccine |FDA_approval=In clinical trials; not yet FDA-approved |used_for=Recurrent heavily pretreated glioblastoma multiforme (GBM) and newly diagnosed GBM |clinical_trial_phase=Phase II |common_side_effects=Not explicitly detailed; similar immunotherapy treatments often include flu-like symptoms, injection site reactions, fatigue |OS_without=Historical controls suggest a median survival t...")
• 14:01, 31 March 2024 Lazy talk contribs created page Dendritic Cell Vaccine (DCVax-L) (Created page with "{{TreatmentInfo |drug_name=Dendritic Cell Vaccine (DCVax-L) |FDA_approval=Under investigation; not yet FDA-approved |used_for=Glioblastoma Multiforme (GBM), both newly diagnosed and recurrent |clinical_trial_phase=Phase 3 |common_side_effects=Intracranial edema, nausea, lymph node infection (rare and manageable) |OS_without=Median overall survival for GBM is typically 15-17 months from diagnosis, or 8 months from recurrence |OS_with=Median overall survival of 19.3 months...")
• 11:03, 31 March 2024 Lazy talk contribs created page Property:Has Toxicity Explanation (Created page with "Has type::Text")
• 21:49, 30 March 2024 Lazy talk contribs created page CPT-11 (Irinotecan) (Created page with "{{TreatmentInfo |drug_name=CPT-11 (Irinotecan) |FDA_approval=Approved for the treatment of colon cancer; under investigation for recurrent glioma |used_for=Recurrent Glioblastoma Multiforme (GBM) and other malignant gliomas |clinical_trial_phase=Phase I/II trials in combination with other therapies |common_side_effects=Hematologic, gastrointestinal, and hepatic toxicities noted; acceptable safety profile in combination regimens |OS_without=Not directly specified; histori...")
• 21:47, 30 March 2024 Lazy talk contribs created page Carboplatin (Created page with "{{TreatmentInfo |drug_name=Carboplatin |FDA_approval=Yes, approved for various cancers including ovarian and lung cancer; used off-label for GBM |used_for=Recurrent Glioblastoma Multiforme (GBM) and high-grade glioma |clinical_trial_phase=Exploratory and Phase 1/2 trials for recurrent glioma in combination with other agents |common_side_effects=Less toxicity compared to cisplatin, but may include myelosuppression, nausea, and potential for liver enzyme elevation |OS_with...")
• 21:45, 30 March 2024 Lazy talk contribs created page Fotemustine (Created page with "{{TreatmentInfo |drug_name=Fotemustine |FDA_approval=Available in Europe, not FDA-approved in the United States for GBM |used_for=Recurrent Glioblastoma Multiforme (GBM) after the standard Stupp protocol treatment |clinical_trial_phase=Varied, with multiple studies evaluating efficacy and optimal scheduling |common_side_effects=Not specified, typical of nitrosoureas may include myelosuppression, nausea, and liver enzyme elevation |OS_without=Not specified |OS_with=Not sp...")
• 21:42, 30 March 2024 Lazy talk contribs created page BCNU (Carmustine) (Created page with "{{TreatmentInfo |drug_name=BCNU (Carmustine) |FDA_approval=Yes, approved for treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas |used_for=Recurrent Glioblastoma Multiforme (GBM) after radiation treatment |clinical_trial_phase=Various, given its long history of use |common_side_effects=Hepatic and pulmonary toxicity, myelosuppression |OS_without=Not specified in the provided context |OS_with=Not specified in the provided context |P...")
• 21:39, 30 March 2024 Lazy talk contribs created page VAL-083 (Dianhydrogalactitol) (Created page with "{{TreatmentInfo |drug_name=VAL-083 (Dianhydrogalactitol) |FDA_approval=Approved in China for CML and lung cancer; not yet approved outside of China for GBM |used_for=Recurrent Glioblastoma Multiforme (GBM) with unmethylated MGMT promoter |clinical_trial_phase=Phase 2 (ongoing evaluation in GBM AGILE for various GBM subtypes) |common_side_effects=Myelosuppression, including neutropenia and lymphopenia; some instances of serious adverse events possibly related to VAL-083 |...")
• 10:20, 30 March 2024 Lazy talk contribs created page Template:CustomTextDisplay (Created page with "{{{Has original text|}}}")
• 10:04, 30 March 2024 Lazy talk contribs created page Next-Generation CAR T-Cell Therapy for GBM (Created page with "{{TreatmentInfo |drug_name=Next-Generation CAR T-Cell Therapy for GBM |FDA_approval=In trial phase for GBM; FDA-approved for other cancers |used_for=Recurrent Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase 1 (INCIPIENT trial among others) |common_side_effects=Fevers, altered mental status shortly after infusion, significant but manageable neurotoxicity |OS_without=Median survival for recurrent GBM typically less than one year |OS_with=Not fully established; dr...") Tag: Visual edit: Switched
• 22:51, 29 March 2024 Lazy talk contribs created page Gamma Knife Radiosurgery (Created page with "{{TreatmentInfo |drug_name=Gamma Knife Radiosurgery (GKRS) for GBM |FDA_approval=Yes |used_for=Newly diagnosed Glioblastoma Multiforme (GBM) |clinical_trial_phase=N/A (Established treatment modality) |common_side_effects=Lower compared to traditional GBM treatments, with no significant radiation-induced toxicities reported in recent studies. |OS_without=14-16 months with standard treatment. |OS_with=Comparable to standard treatment, specifics depend on individual patient...")
• 22:35, 29 March 2024 Lazy talk contribs created page Radiation via Monoclonal Antibodies (Created page with "<includeonly> {| class="wikitable" |- ! Property !! Information |- | Drug Name || Radiation via Monoclonal Antibodies |- | FDA Approval || Under research, not yet FDA-approved for general use |- | Used for || Glioblastoma (GBM) and potentially other high-grade glioma tumors |- | Clinical Trial Phase || Various phases, with some treatments in early clinical trials |- | Common Side Effects || Side effects vary depending on the specific monoclonal antibody and radioactive c...")
• 10:14, 29 March 2024 Lazy talk contribs created page Template:PropertyTableFormat (Created page with "{| class="wikitable" ! Property ! Value |- | Drug Name | {{{Has drug name}}} |- | FDA Approval | {{{Has FDA approval}}} |- | Used For | {{{Used for}}} |- | Clinical Trial Phase | {{{Clinical trial phase}}} |- ... | Toxicity Explanation | {{{Toxicity explanation}}} |- | Description | {{{Book text}}} |}")
• 09:59, 29 March 2024 Lazy talk contribs created page Proton Radiation Therapy (Created page with "{{TreatmentInfo |drug_name=Proton Beam Therapy (PBT) |FDA_approval=Yes |used_for=Glioblastoma and other cancers |clinical_trial_phase=Ongoing research and clinical trials |common_side_effects=Radiation dermatitis, temporary alopecia, radiation otitis, radiation necrosis (more prevalent in PBT group) |OS_without=Data varies; traditional radiation therapies offer median OS of around 16-21 months for glioblastoma |OS_with=High-dose PBT showed a median OS of 65.6 months for...")
• 07:05, 29 March 2024 Lazy talk contribs created page Optune (Created page with "{{TreatmentInfo |drug_name=Optune (Optune Gio® for newer version) |FDA_approval=Approved for newly diagnosed glioblastoma in October 2015; ongoing trials for broader applications |used_for=Newly diagnosed glioblastoma, with trials for other cancers ongoing |clinical_trial_phase=Phase 3 (EF-14 Trial); Phase 3 TRIDENT trial ongoing |common_side_effects=Mild to moderate skin irritation beneath transducer arrays, thrombocytopenia, nausea, constipation, vomiting, fatigue, he...")
• 06:34, 29 March 2024 Lazy talk contribs created page Category:Over-the-Counter Drugs and Supplements (Created page with "The treatments discussed above generally require a physician’s cooperation in prescribing them. However, there are a number of agents available over-the-counter that have promising anti-cancer properties, and it is reasonable to believe that these can increase the chances of surviving. Some of these with supporting clinical evidence (e.g., protonpump inhibitors such as Prilosec) have been discussed above. A frequent conflict between patients and their oncologists is th...")
• 21:19, 27 March 2024 Lazy talk contribs deleted page CCNU (lomustine) (content was: " {{TreatmentInfo |drug_name=CCNU (lomustine) |category=Other Chemotherapy and Cancer Drugs |book_text=A report from Germany combined TMZ with CCNU (lomustine), the nitrosourea component of the PCV combination (52). Patients (N=39) received CCNU on day 1 of each 6-week cycle, and TMZ on days 2-6. Eight patients received intensified doses of both drugs, with somewhat better survival res...", and the only contributor was "Lazy" (talk))
• 21:18, 27 March 2024 Lazy talk contribs created page EGFR inhibitors: Iressa, Tarceva, and Erbitux (gefitinib, erlotinib, and (Created page with " {{TreatmentInfo |drug_name=EGFR inhibitors: Iressa, Tarceva, and Erbitux (gefitinib, erlotinib, and |category=Other Chemotherapy and Cancer Drugs |book_text=cetuximab) These three drugs, which have FDA approval for several different types of cancer, have the common feature that they target a growth-signaling channel known as the epidermal growth factor. Overexpression or mutation of EGF receptors is involved in the growth many different kinds of cancer, including more...")
• 21:15, 27 March 2024 Lazy talk contribs created page CCNU (lomustine) (Created page with " {{TreatmentInfo |drug_name=CCNU (lomustine) |category=Other Chemotherapy and Cancer Drugs |book_text=A report from Germany combined TMZ with CCNU (lomustine), the nitrosourea component of the PCV combination (52). Patients (N=39) received CCNU on day 1 of each 6-week cycle, and TMZ on days 2-6. Eight patients received intensified doses of both drugs, with somewhat better survival results (but with substantially increased toxicity). For present purposes, the results of...")
• 21:05, 27 March 2024 Lazy talk contribs created page Chloroquine and Hydroxychloroquine (Created page with " {{TreatmentInfo |drug_name=Chloroquine and Hydroxychloroquine |category=Repurposed Drugs |book_text=In aseries of studies conducted in Mexico City (23, 24, 25) patients received the traditional chemotherapy agent BCNU, with or without a 150 mg daily dose of chloroquine (the equivalent of 250 mg chloroquine phosphate). The results were that patients receiving chloroquine had a median survival time of 25-33 months, while those receiving BCNU alone had a median survival t...")
• 14:56, 27 March 2024 Lazy talk contribs created page Silibinin (an ingredient in Milk Thistle) (Created page with "{{TreatmentInfo |drug_name=Silibinin (Silymarin) |FDA_approval=No |used_for=Liver and biliary disorders, adjunct agent in cancer treatment |clinical_trial_phase=Investigated primarily in hepatitis and cirrhosis; small studies in cancers such as acute lymphoblastic leukemia, prostate cancer, breast cancer, head and neck cancer, and hepatocellular carcinoma |common_side_effects=Few reported; mainly gastrointestinal disturbances |OS_without=Not specified |OS_with=Not specif...")
• 23:04, 26 March 2024 Lazy talk contribs created page MN-166 (Created page with "{{TreatmentInfo |drug_name=MN-166 (Ibudilast) |FDA_approval=Approved in Japan for post-stroke complications and bronchial asthma; in late-stage clinical development for ALS, Progressive MS, DCM in other regions |used_for=Experimental for ALS, Progressive MS, DCM, glioblastoma, CIPN, Long COVID, and substance use disorder |clinical_trial_phase=Phase 3 for ALS and DCM, Phase 3-ready for Progressive MS, Phase 2 for glioblastoma, Long COVID, and substance use disorder |commo...")
• 22:49, 26 March 2024 Lazy talk contribs created page Letrozole (Created page with "{ "drug_name": "Letrozole", "FDA_approval": "Yes, for breast cancer; not FDA-approved for glioblastoma", "used_for": "Investigational use in glioblastoma based on preclinical studies", "clinical_trial_phase": "Preclinical studies and early research for glioblastoma", "common_side_effects": "Hot flashes, joint pain, nausea, fatigue, and risk of osteoporosis", "OS_with": "Not available; research in glioblastoma is still in early stages", "PFS_with": "Not avai...")
• 01:37, 26 March 2024 Lazy talk contribs created page Category:Repurposed Drugs (Created page with "== List of Repurposed Drugs == {{#ask: Category:Nutraceuticals and Herbals |?Has treatment name=Drug Name |?Has Usefulness Rating=Usefulness Rating |?Has Toxicity Level=Toxicity Level |format=table }}")
• 01:28, 26 March 2024 Lazy talk contribs created page MGMT (Created page with "== The role of MGMT == � A significant advance in determining which patients will benefit from Temodar was reported by the same research group that reported the definitive trial combining Temodar with radiation. Tumor specimens from the patients in that trial were tested for the level of activation of a specific gene involved in resistance to alkylating chemotherapy (which includes temozolomide and the nitrosoureas, BCNU, CCNU, and ACNU). More specifically, there is an...")
• 01:27, 26 March 2024 Lazy talk contribs created page Full text (Created page with "== The role of MGMT == � A significant advance in determining which patients will benefit from Temodar was reported by the same research group that reported the definitive trial combining Temodar with radiation. Tumor specimens from the patients in that trial were tested for the level of activation of a specific gene involved in resistance to alkylating chemotherapy (which includes temozolomide and the nitrosoureas, BCNU, CCNU, and ACNU). More specifically, there is an...")
• 20:38, 25 March 2024 Lazy talk contribs created page Property:Usefulness Rating (Created page with "Has type::Number")
• 06:53, 24 March 2024 Lazy talk contribs created page Property:Usefulness rating (Created page with "Has type::Number")
• 06:42, 24 March 2024 Lazy talk contribs created page Category:Highly Useful Treatments (Created page with "==Highly Useful Treatments== This page lists all treatments within the wiki that have been rated with a usefulness of 4 or 5, indicating promising or highly effective options based on current research and clinical trials. {{#ask: Category:Treatment Usefulness rating::4 OR Usefulness rating::5 |?Has treatment name=Name |?Usefulness rating |?Clinical trial phase=Phase |format=table |link=all |headers=show |searchlabel=View more treatments |class=wikitable sort...")
• 06:32, 24 March 2024 Lazy talk contribs created page VT-122 (Created page with "{{TreatmentInfo |drug_name=VT-122 (Propranolol and Etodolac combination) |FDA_approval=No (VT-122 is an investigational combination of repurposed drugs; Propranolol and Etodolac are FDA-approved for other conditions) |used_for=Investigational use in cancer treatment, specifically targeting cachexia in non-small cell lung cancer, hepatocellular carcinoma, and potentially glioblastoma |clinical_trial_phase=Phase 2 (based on ongoing and completed trials for various cancer t...")
• 06:27, 24 March 2024 Lazy talk contribs created page Angiotensin-II Receptor Blockers (ARB) (Created page with "{{TreatmentInfo |drug_name=Angiotensin-II Receptor Blockers (ARB) |FDA_approval=Yes (for hypertension; repurposed for cancer studies) |used_for=Investigational use in glioblastoma for potential reduction of vasogenic edema and steroid-sparing effects |clinical_trial_phase=Retrospective Studies |common_side_effects=Varies by specific ARB; can include dizziness, hypotension, and renal function alteration |OS_with=Not specified; studies have focused on steroid requirements...")
• 06:23, 24 March 2024 Lazy talk contribs created page Gleevec (Imatinib) (Created page with "{{TreatmentInfo |drug_name=Gleevec (Imatinib) |FDA_approval=Yes (for chronic myelogenous leukemia and other cancers, not specifically approved for gliomas) |used_for=Investigational use in gliomas, specifically targeting overexpression of platelet-derived growth factor receptor (PDGFR) |clinical_trial_phase=Exploratory/Investigational (Specific phase for gliomas not provided) |common_side_effects=Varies; for leukemia treatment includes fluid retention, nausea, muscle cra...")
• 06:14, 24 March 2024 Lazy talk contribs created page Category:Other Chemotherapy and Cancer Drugs (Created page with "Category:Other Chemotherapy and Cancer DrugsThis category encompasses a range of chemotherapy and cancer drugs used in the treatment of glioblastoma and other high-grade gliomas. These treatments are integral to multimodal cancer therapy approaches, combining traditional chemotherapy agents with newer, targeted drugs to improve patient outcomes.List of TreatmentsHere we provide an overview of various chemotherapy and cancer drugs categorized under "Other Chemotherapy and...")
• 06:12, 24 March 2024 Lazy talk contribs created page Bevacizumab (Avastin) (Created page with "{{TreatmentInfo |drug_name=Bevacizumab (Avastin) |FDA_approval=Yes, for recurrent glioblastoma |used_for=Glioblastoma |clinical_trial_phase=Phase III |common_side_effects=Hypertension, proteinuria, and hemorrhage |OS_with=AVAglio trial: 16.8 months; RTOG trial: 15.7 months |usefulness_rating=4 |notes=Avastin improves PFS when used initially, but no significant benefit for overall survival compared to Avastin given at recurrence. |category=Other Chemotherapy and Cancer Dr...")
• 06:11, 24 March 2024 Lazy talk contribs created page Procarbazine (Created page with "{{TreatmentInfo |drug_name=Procarbazine |FDA_approval=Yes |used_for=Glioblastoma |clinical_trial_phase=Not specified |common_side_effects=Hematological toxicity, nausea, and neurological effects |OS_with=Not specified |usefulness_rating=3 |notes=Combination of Temodar and procarbazine showed a high percentage of tumor regressions, suggesting effectiveness. |category=Other Chemotherapy and Cancer Drugs")
• 06:10, 24 March 2024 Lazy talk contribs created page Platinum Compounds (Created page with "{{TreatmentInfo |drug_name=Platinum Compounds (Cisplatin) |FDA_approval=Yes |used_for=Glioblastoma |clinical_trial_phase=Various, including Phase II |common_side_effects=Nephrotoxicity, ototoxicity, and neurotoxicity |OS_with=Not specified |usefulness_rating=3 |notes=Combining Temodar with cisplatin has shown improved PFS-6 in recurrent tumors. A protocol combining Temodar, cisplatin, and etoposide reported median survival of 25 months. |category=Other Chemotherapy and C...")
• 06:10, 24 March 2024 Lazy talk contribs created page BCNU (Carmustine) and Gliadel (Carmustine Wafers) (Created page with "{{TreatmentInfo |drug_name=BCNU and Gliadel Wafers |FDA_approval=Yes |used_for=High-grade gliomas |clinical_trial_phase=Phase III (Europe for Gliadel) |common_side_effects=Low blood counts, pulmonary problems, infection, and seizures for Gliadel |OS_with=Gliadel: 13.9 months median survival; Combination with TMZ: Median survival ranges from 17 to 20.7 months |usefulness_rating=4 |notes=While Gliadel wafers alone offer modest improvement, combining them with the standard...")